Efficacy of CDK4/6 inhibitors in the preoperative setting
| Reference | Therapy | Phase | Patient characteristics | Number of patients | Response rate (%) | Grade 3/4 toxicity |
|---|---|---|---|---|---|---|
| Chow et al 11 | Palbociclib + letrozole (4 months preoperatively) | II, OOTR-N007 | OR+, HER2- postmenopausal tumour >2 cm, not T3 N1, T4 or N 2,3 | 11 (9 completed) of 45 planned; the study is ongoing | pCR 11% PR 78%, RR 89% | 44% neutropenia |
| Ma et al 58 | Anastrozole + goserelin (if premenopausal) + palbociclib | II | OR+, HER2- stage 2 or 3 | 50 (40 evaluable) | Complete cell cycle arrest 85% | NR |
HER2, human epidermal receptor 2; NR, not reported; OR, oestrogen receptor; ORR, overall response rate; pCR, pathological complete response; PR, partial response; RR, response rate.